In a 50-year-old postmenopausal woman with a history of stage II estrogen receptor‑positive breast cancer treated with lumpectomy and radiation, recent unprovoked deep vein thrombosis, and current use of tamoxifen and apixaban, who presents with new vaginal bleeding and vaginal atrophy without visible lesions, what is the next best step in evaluation?

Transvaginal Ultrasonography

The next best step is transvaginal ultrasonography to evaluate the endometrium and rule out endometrial pathology, particularly endometrial hyperplasia or malignancy, which are critical concerns in this tamoxifen-treated patient with postmenopausal bleeding. 1

Clinical Reasoning

This 50-year-old postmenopausal woman presents with a high-risk scenario requiring immediate structural evaluation:

Why Transvaginal Ultrasound is the Priority

• Postmenopausal bleeding is endometrial cancer until proven otherwise - this is the most serious etiology and must be the primary focus of evaluation 1
• Tamoxifen significantly increases endometrial cancer risk (risk ratio 2.53) 2, 3 - the FDA label explicitly warns that this increased risk occurs predominantly in women aged 50 years or older 2
• Transvaginal ultrasound is the first-line imaging modality for evaluating abnormal uterine bleeding in postmenopausal women according to ACR Appropriateness Criteria 1
• The examination findings (vaginal atrophy, small amount of dark blood, no visible lesions) do not exclude endometrial pathology

Why NOT the Other Options

CT abdomen/pelvis is not appropriate as initial imaging:

• Does not adequately visualize endometrial thickness or architecture
• Exposes patient to unnecessary radiation
• Not recommended by guidelines for initial evaluation of postmenopausal bleeding 1

Discontinuing apixaban is inappropriate and potentially dangerous:

• She has an unprovoked DVT only 3 months ago - this requires extended anticoagulation 4, 4
• The FDA label indicates treatment duration for DVT/PE should be at least 6 months 4
• While anticoagulation may contribute to bleeding, the primary concern is identifying the source of bleeding, not the anticoagulant itself 5
• Stopping anticoagulation prematurely dramatically increases thrombotic risk, which could be fatal

No further testing is unacceptable:

• Postmenopausal bleeding mandates evaluation for malignancy
• Tamoxifen use makes this even more urgent given the 2.5-fold increased endometrial cancer risk 2

Next Steps After Ultrasound

Based on transvaginal ultrasound findings:

• If endometrial thickness >4-5mm: Proceed to endometrial sampling (biopsy or dilation and curettage) 1
• If endometrium cannot be adequately visualized: Consider MRI with diffusion-weighted imaging or proceed directly to endometrial sampling 1
• If normal endometrium and persistent bleeding: Consider other sources (cervical, vaginal) or repeat evaluation

Critical Pitfalls to Avoid

1. Do not attribute bleeding solely to anticoagulation without ruling out structural pathology - this is a common error that can delay cancer diagnosis 5
2. Do not stop anticoagulation for a recent unprovoked DVT without compelling indication and alternative thromboprophylaxis
3. Do not delay endometrial evaluation in tamoxifen-treated patients with postmenopausal bleeding - all endometrial cancers in the tamoxifen prevention trial were caught at stage I, emphasizing the importance of prompt evaluation 3

Multidisciplinary Coordination

This patient requires coordinated care between gynecology and hematology/thrombosis specialists 5. If endometrial sampling is needed, temporary interruption of apixaban (24-48 hours depending on bleeding risk of the procedure) may be necessary, but this should be done in consultation with her anticoagulation provider 4, 4.